Nasdaq Biotechnology Ishares ETF (IBB)
$116.88 2.62 (2.19%)
18:48 EST IBB Stock Quote Delayed 15 Minutes
Previous Close $116.88
Market Cap 10.16B
PE Ratio -
Volume (Avg. Vol.) 4.31M
Day's Range 116.27 - 120.00
52-Week Range 96.03 - 123.74
Dividend & Yield 0.31 (0.27%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
- From InvestorPlace
- From the Web
The biotech sector peaked in 2015. While it bounced back from lows, biotech ETFs give investors exposure to the sector as it recovers.
Both biotech stocks and big pharma stocks involve a different mindset. Treat biotech stocks like options and big pharma stocks like ETFs.
The markets had a big week and bulls are looking to press their luck and fatten their wallets. Here are our top stock trades for Monday.
Investors looking for low-cost, diversified exposure to growth stocks are wise to consider one of the 7 best growth ETFs on the market.
TEVA stock has potential that is purely technical. Teva Pharmaceutical is showing a breakout that would send it 25% higher from here, so now is the time to go long.
These biotech and pharmaceutical stocks are soaring insanely high right now. Here's what investors should know about each of these hot stocks to buy.
CELG stock continues to notably lag some of its peers in the biotechnology group, but this could soon change and set up a juicy Celgene trade.
A 50% pop on speculation is as good a reason to short JUNO stock as any. This is how you should play Juno Therapeutics now.
We will start to see whether investor optimism has been converted into sales this earnings season, which will get into full swing in the next few weeks. In the meantime, I'm looking to trade one of my favorite bullish themes: biotech.
The reappearance of inflationary pressure will put a lid on markets soon, and the resulting flash crash will hurt these five stocks the most.
Biotech stocks are scary when they are falling. Sell downside risk into BIIB stock support with confidence for a chance at free profits.
CELG stock for the first time in a couple of months is showing a more promising near-term buy signal. Celgene's reward to risk is promising.
Biotech companies are still under threat from the White House. So I sell risk in Mylan for income into those fears. Bet on MYL stock support for cash.
After a long stint of selling, AGN stock is finally showing signs of stabilization. I want to generate income from Allergan support.
Biotech falling knives like Amgen are notoriously dangerous, but AMGN stock has value against which I am willing to bet bullish.
This latest pullback in AMGN stock now looks to provide a better reward-to-risk opportunity to buy Amgen again.